Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).

被引：0
|
作者：
Thomson, Alastair
Pollard, Adam
Mark, Frances May
机构：
[1] Royal Cornwall Hosp, Truro, England
[2] Royal Cornwall Hosp Trust, Truro, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.298
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
298
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Karnes, R. Jeffrey
    Ahmed, Mohamed E.
    [J]. APPLIED RADIOLOGY, 2021, 50 (01) : 42 - 43
  • [2] Impact of comorbidity on outcome in men with metastatic castrate-resistant prostate cancer (mCRPC)
    Zist, A.
    Amir, E.
    Ocana, A.
    Seruga, B.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S703 - S703
  • [3] Elderly patients with metastatic castrate-resistant prostate cancer (mCRPC): Safety and efficacy of docetaxel retreatment
    Gernone, A.
    Pagliarulo, A.
    Calderoni, G.
    Pagliarulo, V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [4] Intermittent Docetaxel Chemotherapy in Patients With Castrate-resistant Prostate Cancer
    Mountzios, Ioannis
    Bournakis, Evangelos
    Efstathiou, Eleni
    Varkaris, Andreas
    Wen, Sijin
    Chrisofos, Michael
    Deliveliotis, Charalambos
    Alamanis, Christos
    Anastasiou, Ioannis
    Constantinides, Constantine
    Karadimou, Alexandra
    Tsiatas, Marinos
    Papadimitriou, Christos
    Bamias, Aristotelis
    Dimopoulos, Meletios A.
    [J]. UROLOGY, 2011, 77 (03) : 682 - 687
  • [5] Docetaxel chemotherapy for Chinese patients with castrate-resistant prostate cancer
    Cheung, F. Y.
    Leung, K. C.
    Ngan, Roger K. C.
    [J]. HONG KONG MEDICAL JOURNAL, 2013, 19 (03) : 237 - 241
  • [6] Management of Docetaxel Failures in Metastatic Castrate-Resistant Prostate Cancer
    Pal, Sumanta K.
    Lewis, Brian
    Sartor, Oliver
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 2012, 39 (04) : 583 - +
  • [7] Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Theoret, Marc Robert
    Arlen, Philip M.
    Dawson, Nancy Ann
    Rosner, Inger L.
    McLeod, David G.
    Wright, John Joseph
    Cordes, Lisa M.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Trepel, Jane B.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [8] Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease
    Schmidt, Andrew Lachlan
    Anton, Angelyn
    Wong, Shirley S.
    Azad, Arun
    Kwan, Edmond Michael
    Spain, Lavinia Anne
    Torres, Javier
    Muthusamy, Arunbalaji
    Parente, Phillip
    Parnis, Francis
    Goh, Jeffrey C.
    Joshua, Anthony M.
    Pook, David William
    Gibbs, Peter
    Tran, Ben
    Weickhardt, Andrew James
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [9] A castrate-resistant metastatic prostate cancer patient with severe pancytopenia, successfully treated with docetaxel chemotherapy
    Kunthur, Anuradha
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (05) : 1254 - 1258
  • [10] Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial
    Horgan, Anne M.
    Seruga, Bostjan
    Pond, Greg R.
    Alibhai, Shabbir M.
    Amir, Eitan
    De Wit, Ronald
    Eisenberger, Mario A.
    Tannock, Ian F.
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2014, 5 (02) : 119 - 126
12345